Evidence map›Paper›PMID 38514187›Full record

ArticleLife science alliance2024

The Rtf1/Prf1-dependent histone modification axis counteracts multi-drug resistance in fission yeast.

Jennifer J Chen, Calvin Moy, Viviane Pagé, Cian Monnin, Ziad W El-Hajj, Daina Z Avizonis, Rodrigo Reyes-Lamothe, Jason C Tanny

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life science alliance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jennifer J ChenDepartment of Pharmacology and Therapeutics, McGill University, Montreal, Canada.
Calvin MoyDepartment of Pharmacology and Therapeutics, McGill University, Montreal, Canada.
Viviane PagéDepartment of Pharmacology and Therapeutics, McGill University, Montreal, Canada.
Cian MonninMetabolomics Innovation Resource, Goodman Cancer Institute, McGill University, Montreal, Canada.
Ziad W El-HajjDepartment of Biology, McGill University, Montreal, Canada.
Daina Z AvizonisMetabolomics Innovation Resource, Goodman Cancer Institute, McGill University, Montreal, Canada.
Rodrigo Reyes-LamotheDepartment of Biology, McGill University, Montreal, Canada.
Jason C TannyDepartment of Pharmacology and Therapeutics, McGill University, Montreal, Canada jason.tanny@mcgill.ca.ORCID 0000-0003-3495-6150
McGill University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA polymerase II transcription elongation directs an intricate pattern of histone modifications. This pattern includes a regulatory cascade initiated by the elongation factor Rtf1, leading to monoubiquitylation of histone H2B, and subsequent methylation of histone H3 on lysine 4. Previous studies have defined the molecular basis for these regulatory relationships, but it remains unclear how they regulate gene expression. To address this question, we investigated a drug resistance phenotype that characterizes defects in this axis in the model eukaryote

Indexed as

SchizosaccharomycesDrug Resistance, MultipleHistone CodeHistonesRNA Polymerase IIHistonesRNA Polymerase II

Identifiers

PMID38514187
PMCPMC10958104
OpenAlexW4393028847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.